After a CMS rule change in August, UnitedHealthcare is introducing step therapy in Medicare Advantage plans to favor biosimilars over certain brands.
Amazon's plan to jump into drug sales has hit a snag, and the retail giant has reportedly put at least one plan on ice.
J&J paid out $15 billion in rebates and discounts in 2017 as its average selling price slipped 4.6%.
In the wake of the Aetna-CVS combo, Cigna's Express Scripts buy could mean more pricing resistance ahead for drugmakers.
UnitedHealthcare is planning to offer rebates directly back to millions of patients—a move that addresses a top criticism from the drug industry.
The decision by two leading pharmacy benefit managers to exclude Sanofi's big-sellers in diabetes took a toll in 2017.
A California legislator is targeting pharma's use of copay coupons to promote pricey branded meds over cheaper alternatives.